Mirielle GillingsMireille Gillings, PhD, Hon DSc

CHIEF EXECUTIVE OFFICER & EXECUTIVE CHAIR

Dr. Gillings has 25 years of experience in the biotechnology industry with a unique balance of scientific and operational experience. She founded HUYA Bioscience International and has grown this privately-held company to become the global leader in accelerating the development of novel biopharmaceutical product opportunities originating in China in worldwide markets. She is the vice chair and co-founder of GHO Capital, a private equity fund specializing in global health; has served on the board of Quintiles, now IQVIA, a Fortune 500 company, where she was a member of the Governance, Quality and Nominating Committee; is a board member of Senté Inc, a private science-based skincare company; and serves on the Pasteur Institute Advisory Board.

Robert Goodenow, PhD

Robert Goodenow, PhD

President

Dr. Goodenow has over 30 years experience in the pharmaceutical industry. His leadership roles in executive and senior management have encompassed R&D, business development, licensing, and commercialization including market launch. Dr. Goodenow was previously Chief Business Officer at Syndax where he led business and commercial development efforts for their epigenetic oncology program.

Clement GingrasClement Gingras

CHIEF TECHNOLOGY OFFICER & CHIEF OPERATING OFFICER, ASIA

Mr. Gingras has 25 years experience in international management and operations for brands such as Ericsson, the global communications company. At HUYABIO he is responsible for the company’s presence in Asia where he directs all China operations and business development. Mr. Gingras also manages the company’s compound database, the world’s most comprehensive portfolio of novel Chinese compounds.

Kenneth PolinKenneth D. Polin, Esq.

CHIEF ADMINISTRATIVE OFFICER & GENERAL COUNSEL

Mr. Polin has over 35 years of experience including the areas of securities, venture capital, and strategic relationships. Most recently, Mr. Polin was a corporate partner with Jones Day. Mr. Polin has been counsel to companies in the biotechnology, health care, medical device, telecommunications and is a member of the State Bar of California. He has managed a broad range of major business transactions, including private placements and public offerings.

Jonathan-OConnellJonathan O’Connell

CHIEF FINANCIAL OFFICER

Mr. O’Connell has over 25 years experience, with deep expertise and understanding of both the life science and technology industries, including leading fundraisings, public listings, acquisitions and trade sales. He previously served as the CFO and Director of Escher Group Holdings. Before this Mr. O’Connell was CFO and Director of Merrion Pharmaceuticals PLC.

Martin DoorbarMartin Doorbar

GLOBAL HEAD CMC AND MANUFACTURING OPERATIONS

Dr. Doorbar has over 25 years experience of drug and medical device development and extensive knowledge of manufacturing. In his 10 years at Shire Pharmaceuticals, Mr. Doorbar has overseen successful filing and approvals for 11 commercial product NDAs, MAAs across the US, EU and Asia in addition to 30 successful INDs/IMPDs globally for phase I– IV clinical studies.